This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

High Dose BAYA1040_Nifedipine: a Long Term Combination Study

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: February 10, 2011
Last updated: June 20, 2014
Last verified: June 2014
This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) with other antihypertensives in patients with essential hypertension who are not at target blood pressure by the combination of BAYA1040_Nifedipine 40 mg once daily and other antihypertensives.

Condition Intervention Phase
Hypertension Drug: Nifedipine (Adalat, BAYA1040) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open Label, Long Term Study of Oral BAYA1040_CR 80 mg (40 mg Bid) in Combination With Other Antihypertensives for 52 Weeks in Patients With Essential Hypertension

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Efficacy changes measured by sitting diastolic blood pressure (DBP) [ Time Frame: Up to 52 weeks ]

Secondary Outcome Measures:
  • Efficacy changes measured by sitting systolic blood pressure (SBP) [ Time Frame: Up to 52 weeks ]
  • Proportion of subjects achieving a target BP based on the Japanese Society of Hypertension (JSH) 2009 guidelines [ Time Frame: Up to 52 weeks ]
  • Proportion of subjects achieving a target DBP and SBP based on JSH 2009 guidelines or a >10 mmHg reduction of DBP [ Time Frame: Up to 52 weeks ]
  • Safety variables [ Time Frame: Up to 30 days after the last dose of study drug ]
    Adverse events, vital signs, electrocardiography (ECG), and laboratory tests were evaluated.

Enrollment: 72
Study Start Date: February 2011
Study Completion Date: June 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Nifedipine (Adalat, BAYA1040)
Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 20 years or older
  • Japanese male or female
  • Outpatient with essential hypertension
  • Patients who are treated with Adalat CR 40 mg od and at least one antihypertensive drug (other than Ca antagonists) for 4 weeks or more before entry in this study

Exclusion Criteria:

  • Patients whose sitting diastolic blood pressure (DBP) is 110 mm Hg or more
  • Patients with secondary hypertension or hypertensive emergency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01294215

Ebina, Kanagawa, Japan, 243-0401
Sagamihara, Kanagawa, Japan, 252-0311
Kawaguchi, Saitama, Japan, 332-0012
Shinjuku, Tokyo, Japan, 169-0072
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT01294215     History of Changes
Other Study ID Numbers: 14024
Study First Received: February 10, 2011
Last Updated: June 20, 2014

Keywords provided by Bayer:
Essential hypertension
Japanese Patients
Phase III
combination study

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs processed this record on August 23, 2017